Kolon TissueGene (XKRX:950160) Total Assets : ₩192,873 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Kolon TissueGene Total Assets?

Kolon TissueGene's Total Assets for the quarter that ended in Sep. 2024 was ₩192,873 Mil.

Warning Sign:

If a company builds assets at 48.1% a year, faster than its revenue growth rate of 7% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Kolon TissueGene's average Total Assets Growth Rate was 75.20% per year. During the past 3 years, the average Total Assets Growth Rate was 86.70% per year. During the past 5 years, the average Total Assets Growth Rate was 48.10% per year.

During the past 8 years, Kolon TissueGene's highest 3-Year average Total Assets Growth Rate was 86.70%. The lowest was 18.90%. And the median was 39.40%.

Total Assets is connected with ROA %. Kolon TissueGene's annualized ROA % for the quarter that ended in Sep. 2024 was -12.45%. Total Assets is also linked to Revenue through Asset Turnover. Kolon TissueGene's Asset Turnover for the quarter that ended in Sep. 2024 was 0.01.

Kolon TissueGene Total Assets Historical Data

The historical data trend for Kolon TissueGene's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon TissueGene Total Assets Chart

Kolon TissueGene Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

124,093.08

72,838.60

61,399.48

109,889.90

134,910.38

Kolon TissueGene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															146,233.26	134,910.38	140,834.31	183,595.16	192,872.64

Kolon TissueGene Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Kolon TissueGene's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	114963.38	+	19947.001
	=	134,910

Kolon TissueGene's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	148868.303	+	44004.341
	=	192,873

Kolon TissueGene (XKRX:950160) Total Assets Explanation

Total Assets is connected with ROA %.

Kolon TissueGene's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-23444.5	/	( (183595.156	+	192872.644)	/ 2 )
	=	-23444.5	/	188233.9
	=	-12.45 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Kolon TissueGene's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	2098.277	/	( (183595.156	+	192872.644)	/ 2 )
=	2098.277	/	188233.9
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Kolon TissueGene Total Assets Related Terms

Thank you for viewing the detailed overview of Kolon TissueGene's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Kolon TissueGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kolon TissueGene Inc (XKRX:950160) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

9713 Key West Avenue, Suite 300, Rockville, MD, USA, 20850

Website

https://www.tissuegene.com

Kolon TissueGene Inc is a biopharmaceutical company that develops regenerative therapies for the treatment of various orthopedic disorders. It is developing four product candidates, TG-C, TG-B, TG-D and TG-N for regeneration of cartilage, bone, disc and nerve.

Kolon TissueGene Headlines

No Headlines